Grant: CIHR Fellowship
Université de Montréal
$135,000.00
Multigenic analysis and chemical drug screening using in vivo zebrafish models of motor neurodegenerative disorders
EF 2010-11
Résumé
The concept of genetic networks spaning neurodegenerative diseases has been emerging, with some genes playing pivotal roles, such as the TDP-43 encoding TARDBP gene which is mutated in Amyotrophic Lateral Sclerosis (ALS). ALS is a genetic neurodegenerative disorder characterized by the death of large motor neurons in the cerebral cortex and spinal cord. Mutations in the TARDBP and FUS genes account for nearly 3% of cases.
The Drapeau lab has extensive expertise in zebrafish spinal cord neurobiology and models of hereditary neurodegenerative diseases, including ALS. They showed that TARDBP and FUS genes interact in a common pathogenic pathway. Moreover, they have created a stable inducible transgenic zebrafish which displays a progressive motor neuron disorder mimicking disease progression.
In this research project, we propose to do multigenic analyses using zebrafish model in order to delineate the genetic network of the ALS-associated TARDBP gene. This will allow characterization of molecular pathways shared by the broad spectrum of neurodegenerative disorders. We also propose to develop new transgenic zebrafish models of ALS, which will be uniquely useful to better understand the disease mechanism. In addition, we plan to screen libraries of several thousand small chemicals, including clinically approved drugs, for their ability to suppress the pathogenic phenotypes in order to discover molecules with therapeutic potential. As the molecular mechanism leading to neuronal degeneration is still unknown, it is not yet possible to perform direct chemical in vitro screens. Large scale chemical genetic screens in zebrafish models of human diseases have already led to the identification of several molecules which are currently in clinical trials; thus, we believe that these in vivo zebrafish models are the best starting point to develop a pharmacological screening approach to discover therapies for this devastating disorder.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
225315
Name
Boissel Sarah
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Multigenic analysis and chemical drug screening using in vivo zebrafish models of motor neurodegenerative disorders
Programtype2
Fellowship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Amyotrophic Lateral Sclerosis; Ataxia; Atx2; Chemical Screen; Fus; Genetic Interaction; Smn1; Spinal Muscular Atrophy; Stable Transgenic Models; Tardbp; Therapeutic Compounds; Zebrafish Models
Abstract
The concept of genetic networks spaning neurodegenerative diseases has been emerging, with some genes playing pivotal roles, such as the TDP-43 encoding TARDBP gene which is mutated in Amyotrophic Lateral Sclerosis (ALS). ALS is a genetic neurodegenerative disorder characterized by the death of large motor neurons in the cerebral cortex and spinal cord. Mutations in the TARDBP and FUS genes account for nearly 3% of cases.
The Drapeau lab has extensive expertise in zebrafish spinal cord neurobiology and models of hereditary neurodegenerative diseases, including ALS. They showed that TARDBP and FUS genes interact in a common pathogenic pathway. Moreover, they have created a stable inducible transgenic zebrafish which displays a progressive motor neuron disorder mimicking disease progression.
In this research project, we propose to do multigenic analyses using zebrafish model in order to delineate the genetic network of the ALS-associated TARDBP gene. This will allow characterization of molecular pathways shared by the broad spectrum of neurodegenerative disorders. We also propose to develop new transgenic zebrafish models of ALS, which will be uniquely useful to better understand the disease mechanism. In addition, we plan to screen libraries of several thousand small chemicals, including clinically approved drugs, for their ability to suppress the pathogenic phenotypes in order to discover molecules with therapeutic potential. As the molecular mechanism leading to neuronal degeneration is still unknown, it is not yet possible to perform direct chemical in vitro screens. Large scale chemical genetic screens in zebrafish models of human diseases have already led to the identification of several molecules which are currently in clinical trials; thus, we believe that these in vivo zebrafish models are the best starting point to develop a pharmacological screening approach to discover therapies for this devastating disorder.
Competitiondate
201102
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Boissel, Sarah
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~